menu
    • menu
    [{"orgOrder":0,"company":"JSR Life Sciences","sponsor":"Vedanta Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Series C Financing","leadProduct":"VE202","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"JSR Life Sciences","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"JSR Life Sciences \/ JSR","highestDevelopmentStatusID":"6","companyTruncated":"JSR Life Sciences \/ JSR"},{"orgOrder":0,"company":"KBI Biopharma","sponsor":"BITT","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"BITR2101","moa":"TNFR2","graph1":"Oncology","graph2":"IND Enabling","graph3":"KBI Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"KBI Biopharma \/ Boston Immune Technologies and Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"KBI Biopharma \/ Boston Immune Technologies and Therapeutics"},{"orgOrder":0,"company":"KBI Biopharma","sponsor":"Pandion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"PT627","moa":"PD-1","graph1":"Immunology","graph2":"Preclinical","graph3":"KBI Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"KBI Biopharma \/ Pandion Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"KBI Biopharma \/ Pandion Therapeutics"},{"orgOrder":0,"company":"KBI Biopharma","sponsor":"AM-Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"Ilofotase Alfa","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"KBI Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"KBI Biopharma \/ AM-Pharma","highestDevelopmentStatusID":"10","companyTruncated":"KBI Biopharma \/ AM-Pharma"},{"orgOrder":0,"company":"KBI Biopharma","sponsor":"KBI Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Agreement","leadProduct":"IMA402","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"KBI Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"KBI Biopharma \/ KBI Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"KBI Biopharma \/ KBI Biopharma"},{"orgOrder":0,"company":"KBI Biopharma","sponsor":"Hemogenyx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"CDX bi-specific antibodies","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"KBI Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"KBI Biopharma \/ Selexis","highestDevelopmentStatusID":"4","companyTruncated":"KBI Biopharma \/ Selexis"},{"orgOrder":0,"company":"KBI Biopharma","sponsor":"Generium JSC","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Omalizumab","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"KBI Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"KBI Biopharma \/ Generium JSC","highestDevelopmentStatusID":"12","companyTruncated":"KBI Biopharma \/ Generium JSC"},{"orgOrder":0,"company":"KBI Biopharma","sponsor":"NexImmune","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"HLA IgG4 Fusion Proteins","moa":"T cell","graph1":"Oncology","graph2":"Preclinical","graph3":"KBI Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"KBI Biopharma \/ NexImmune","highestDevelopmentStatusID":"4","companyTruncated":"KBI Biopharma \/ NexImmune"},{"orgOrder":0,"company":"JSR Life Sciences","sponsor":"Blau Farmaceutica","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"Epoetin Alfa","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"JSR Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"JSR Life Sciences \/ Blau Farmaceutica","highestDevelopmentStatusID":"12","companyTruncated":"JSR Life Sciences \/ Blau Farmaceutica"},{"orgOrder":0,"company":"KBI Biopharma","sponsor":"Mapp Biopharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"MBP134","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"KBI Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"KBI Biopharma \/ KBI Biopharma","highestDevelopmentStatusID":"5","companyTruncated":"KBI Biopharma \/ KBI Biopharma"},{"orgOrder":0,"company":"JSR Life Sciences","sponsor":"Similis Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"JSR Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"JSR Life Sciences \/ Similis Bio","highestDevelopmentStatusID":"4","companyTruncated":"JSR Life Sciences \/ Similis Bio"}]

    Find Clinical Drug Pipeline Developments & Deals by JSR Life Sciences

    Menu

    JSR Life Sciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    EXCIPIENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            JSR Life Sciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            JSR Life Sciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Similis Bio

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Similis Bio Partners With Novel351k to Develop Multiple Biosimilar Programs Targeting Cancer and Autoimmune Di...

                            Details : Under the terms of the partnership, Novel351k will leverage its experience with regulatory and clinical strategies to accelerate the development of three biosimilar programs that address a wide range of hard-to-treat diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            February 14, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Similis Bio

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            KBI Biopharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            KBI Biopharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MBP134

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Recipient : Mapp Biopharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            KBI Biopharma Announces Subcontract with Mapp Biopharmaceutical on Sudan Ebolavirus Treatment

                            Details : The agreement is signed for the continued development and manufacturing of MBP134, an experimental combination monoclonal antibody treatment for Sudan ebolavirus (SUDV).

                            Brand Name : MBP134

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 23, 2023

                            Lead Product(s) : MBP134

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Recipient : Mapp Biopharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            JSR Life Sciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            JSR Life Sciences

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Erythropoietin EPO

                            Therapeutic Area : Hematology

                            Study Phase : Approved

                            Sponsor : Blau Farmaceutica

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Similis Bio Partners With Blau Farmaceutica to Co-Develop Four Biosimilar Programs

                            Details : The agreement, Blau’s most recent move into the biosimilars market, is a multi-product and multi-year deal to develop products and licenses IP for four biosimilar assets targeting indications in oncology, inflammation, and blood disorders.

                            Brand Name : rHuEPO

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 25, 2022

                            Lead Product(s) : Erythropoietin EPO

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved

                            Sponsor : Blau Farmaceutica

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            KBI Biopharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            KBI Biopharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HLA IgG4 Fusion Proteins,T-cell Co-stimulatory Monoclonal Antibodies

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : NexImmune

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Au...

                            Details : The agreement supports the development of molecules targeting acute myeloid leukemia, multiple myeloma, human papilloma virus (HPV) associated tumors, and additional human leukocyte antigens (HLAs) that have the potential to increase immunotherapy option...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 08, 2022

                            Lead Product(s) : HLA IgG4 Fusion Proteins,T-cell Co-stimulatory Monoclonal Antibodies

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : NexImmune

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            KBI Biopharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            KBI Biopharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omalizumab

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Approved

                            Sponsor : Generium JSC

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Launch of Generium’s Omalizumab Biosimilar for Atopic Bronchial Asthma Marks Selexis’ Ninth Commercial Pro...

                            Details : Genolar, Generium’s biosimilar of omalizumab is third Selexis SUREtechnology Platform generated to reach market, is a recombinant humanized IgG1k monoclonal antibody biosimilar that binds to free human immunoglobulin E for the treatment of persistent a...

                            Brand Name : Genolar

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 09, 2022

                            Lead Product(s) : Omalizumab

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Approved

                            Sponsor : Generium JSC

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            KBI Biopharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            KBI Biopharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CDX bi-specific antibodies

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Hemogenyx Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Hemogenyx Pharmaceuticals and Selexis SA Will Advance Hemogenyx’s Acute Myeloid Leukemia (AML) CDX Bispecifi...

                            Details : Under the agreement, Hemogenyx will leverage Selexis’ proprietary SUREtechnology Platform™, a suite of cell line development tools and technologies that significantly reduces the time, effort, and costs associated with developing high-performance mam...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 12, 2022

                            Lead Product(s) : CDX bi-specific antibodies

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Hemogenyx Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            KBI Biopharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            KBI Biopharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMA402

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : KBI Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Selexis and KBI Biopharma Enter into Agreements with Immatics for Integrated Approach to Advance Immatics TCR ...

                            Details : Under the agreements, Selexis will utilize its SUREtechnology Platform™ and KBI will leverage its advanced analytics, process, formulation and cGMP manufacturing for Immatics’ IMA402 program.

                            Brand Name : IMA402

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            June 29, 2021

                            Lead Product(s) : IMA402

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : KBI Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            KBI Biopharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            KBI Biopharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ilofotase Alfa

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : AM-Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            KBI Biopharma Enters Commercial Manufacturing Agreement with AM-Pharma to Prepare for the Commercial Launch Ac...

                            Details : KBI will conduct manufacturing and validation in its existing facilities. AM-Pharma and KBI Biopharma began collaborating on the recAP program in 2011 when KBI performed initial process development and cGMP manufacturing for early clinical use.

                            Brand Name : recAP

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 17, 2021

                            Lead Product(s) : Ilofotase Alfa

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : AM-Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            KBI Biopharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            KBI Biopharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PT627

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Pandion Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Selexis Enters Service Agreement with Pandion Therapeutics to Advance Pandion Antibody

                            Details : Under the terms of the agreement, Pandion will utilize Selexis’ proprietary SUREtechnology Platform™ to rapidly develop the research cell banks (RCBs) necessary to advance PT627 to human trials.

                            Brand Name : PT627

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 16, 2021

                            Lead Product(s) : PT627

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Pandion Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            KBI Biopharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            KBI Biopharma

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BITR2101

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : BITT

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Selexis and Boston Immune Technologies and Therapeutics (BITT) Enter Service Agreement to Advance BITT’s Lea...

                            Details : The agreement focuses to develop the cell line for BITR2101, BITT’s lead tumor necrosis factor receptor 2 (TNFR2) antagonist antibody for the treatment of cancers and infectious diseases.

                            Brand Name : BITR2101

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 09, 2021

                            Lead Product(s) : BITR2101

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : BITT

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth